Search results: (10000)
News Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple pharmacokinetic protocol for patients with hemophilia A.
News Efficacy and Safety of the Combination of Telmisartan and Amlodipine with Hydrochlorothiazide in the Treatment of Hypertension
The aim of the study by Korean authors was to evaluate the efficacy and tolerability of the triple combination of telmisartan/amlodipine + hydrochlorothiazide (TAH) compared to the combination of telmisartan/amlodipine (TA) alone in patients with essential hypertension who did not respond sufficiently to a 4-week treatment with TA.
News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.
News Anticoagulation Therapy in Patients on ECMO During the COVID-19 Pandemic
In the past 2 years, the use of extracorporeal membrane oxygenation (ECMO) in intensive care units (ICU) has increased in connection with the treatment of severe COVID-19 pneumonia. Dr. Pilar Marcos Neira from the ICU at Germans Trias i Pujol Hospital in Barcelona has compiled a summary of updated knowledge on anticoagulation therapy in these patients.
News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice
Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?
News What is the effectiveness of levodropropizine in the treatment of children's cough?
Levodropropizine represents an effective and safe option for the treatment of acute irritating cough in children. How does it compare to dropropizine and commonly used centrally acting antitussives?
News Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) – newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).
News Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors – brigatinib, followed by lorlatinib – in real-world clinical practice.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab vedotin in patients after autologous stem cell transplantation were presented.
News Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule − inclisiran were presented at the Novartis company symposium.
News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
News Cenobamate − A Case Study from Slovak Real Practice
Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary generalization in adult patients who have not achieved sufficient results with previous treatment with at least 2 antiepileptics. This new anti-seizure medication with a dual mechanism of action thus brings another therapeutic option for patients refractory to treatment. At the November 34th Slovak-Czech Epileptology Congress in Bratislava, during a symposium titled “Is there hope for a quality life with epilepsy?” doc. MUDr. Eva Feketeová, PhD., from the Neurological Clinic LF UPJŠ and UNLP in Košice shared her first experiences with cenobamate in clinical practice.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema – Case Study
Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.